We are live on ! Find out more

Verastem

VSTM

Market cap $1.18B

9.75 USD

+0.09

0.93%

At close Updated Oct 30, 4:00 PM EDT

Pre-market

After hours

9.77

+0.02

0.21%

1 day

0.93%

5 days

-2.5%

1 month

21.12%

3 months

59.84%

6 months

78.57%

Year to date

34.85%

1 year

5.63%

5 years

-69.91%

10 years

-35%

About: Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Employees: 102

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 34.8%

Neutral 65.2%

Negative 0%

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its third quarter 2026 financial results and business updates on Thursday, November 5, 2026, at 4:30 pm ET. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Invest.

Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026

Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript

Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript

Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript

Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

Verastem NASDAQ: VSTM presented updated clinical data for VS-7375, an oral, highly selective KRAS G12D inhibitor, from its ongoing TARGET-D 101 study in patients with pancreatic ductal adenocarcinoma, colorectal cancer and non-small cell lung cancer. The company also outlined plans for registrational Phase II studies and frontline Phase III trials.

Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers

Verastem Oncology (NASDAQ:VSTM) reported encouraging early clinical results for its experimental KRAS G12D inhibitor VS-7375, with the drug demonstrating antitumor activity across pancreatic, colorectal, and lung cancers, alongside a favorable safety profile.

Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers

Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug

Verastem plans to raise $250 million as it prepares for late-stage testing of its experimental cancer treatment.

Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its common stock at an offering price of $8.00 per share, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 312,503 shares of its.

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective January 1, 2027. Mr. Bailey will also continue to serve on the Company's Board of Directors. The CEO transition follows the planned retirement of Daniel Paterson, who will step down as President and CEO and cont.

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

BOSTON--(BUSINESS WIRE)---- $VSTM #CRC--VS-7375 demonstrates robust clinical activity with favorable safety and tolerability in KRAS G12D-mutated pancreatic, lung and colorectal cancers.

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)

Zacks Investment Research

Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?

The consensus price target hints at a 79% upside potential for Verastem (VSTM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?

Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch

Verastem is performing commercially with Avmapki Fakzynja Co-pack and advancing in the clinic with its KRAS G12D inhibitor, VS-7375, in multiple cancers. Q2 '26 net product revenues reached $25.1M in just the fourth quarter of the launch of Co-pack. An October readout from the TARGET-D 101 trial of VS-7375 in solid tumors represents a significant near-term clinical catalyst.

Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch

See News Rankings

Price charts implemented using Lightweight Charts™